171 related articles for article (PubMed ID: 9420657)
1. Vesnarinone: a new inotropic agent for treating congestive heart failure.
Cavusoglu E; Frishman WH; Klapholz M
J Card Fail; 1995 Jun; 1(3):249-57. PubMed ID: 9420657
[TBL] [Abstract][Full Text] [Related]
2. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group.
Feldman AM; Bristow MR; Parmley WW; Carson PE; Pepine CJ; Gilbert EM; Strobeck JE; Hendrix GH; Powers ER; Bain RP
N Engl J Med; 1993 Jul; 329(3):149-55. PubMed ID: 8515787
[TBL] [Abstract][Full Text] [Related]
3. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure.
Matsumori A; Shioi T; Yamada T; Matsui S; Sasayama S
Circulation; 1994 Mar; 89(3):955-8. PubMed ID: 8124835
[TBL] [Abstract][Full Text] [Related]
4. Effect of vesnarinone on cardiac function in patients with severe congestive heart failure.
Scherrer-Crosbie M; Cocca-Spofford D; DiSalvo TG; Semigran MJ; Dec GW; Picard MH
Am Heart J; 1998 Nov; 136(5):769-77. PubMed ID: 9812070
[TBL] [Abstract][Full Text] [Related]
5. [Effect of Chinese-made vesnarinone on experimental heart failure of dog].
Du J; Yang Z
Hua Xi Yi Ke Da Xue Xue Bao; 1992 Jun; 23(2):178-80. PubMed ID: 1452153
[TBL] [Abstract][Full Text] [Related]
6. Dose dependence of chronic positive inotropic effect of vesnarinone in patients with congestive heart failure due to idiopathic or ischemic cardiomyopathy.
Kass DA; Van Anden E; Becker LC; Kasper EK; White WB; Feldman AM
Am J Cardiol; 1996 Sep; 78(6):652-6. PubMed ID: 8831399
[TBL] [Abstract][Full Text] [Related]
7. Inotropic agent vesnarinone inhibits cytokine production and E-selectin expression in human umbilical vein endothelial cells.
Sato Y; Matsumori A; Sasayama S
J Mol Cell Cardiol; 1995 Oct; 27(10):2265-73. PubMed ID: 8576941
[TBL] [Abstract][Full Text] [Related]
8. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators.
Cohn JN; Goldstein SO; Greenberg BH; Lorell BH; Bourge RC; Jaski BE; Gottlieb SO; McGrew F; DeMets DL; White BG
N Engl J Med; 1998 Dec; 339(25):1810-6. PubMed ID: 9854116
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics of vesnarinone.
Feldman AM
Drug Saf; 2004; 27 Suppl 1():1-9. PubMed ID: 15293848
[TBL] [Abstract][Full Text] [Related]
10. Vesnarinone: a potential cytokine inhibitor.
Sasayama S; Matsumori A
J Card Fail; 1996 Sep; 2(3):251-8. PubMed ID: 8891863
[TBL] [Abstract][Full Text] [Related]
11. Carvedilol and vesnarinone: new antiarrhythmic approach in heart failure therapy.
Cheng JH; Kamiya K; Kodama I
Acta Pharmacol Sin; 2001 Mar; 22(3):193-200. PubMed ID: 11742564
[TBL] [Abstract][Full Text] [Related]
12. Inotropic agents and immune modulation.
Sasayama S
Cardiovasc Drugs Ther; 2002 May; 16(3):237-43. PubMed ID: 12374902
[TBL] [Abstract][Full Text] [Related]
13. Effects of vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure: a report from the Vesnarinone Trial.
Deswal A; Petersen NJ; Feldman AM; White BG; Mann DL
Chest; 2001 Aug; 120(2):453-9. PubMed ID: 11502643
[TBL] [Abstract][Full Text] [Related]
14. Nonglycoside inotropes in congestive heart failure. Are they beneficial or harmful?
Chatterjee K; Wolfe CL; DeMarco T
Cardiol Clin; 1994 Feb; 12(1):63-72. PubMed ID: 8181026
[TBL] [Abstract][Full Text] [Related]
15. Effect of inotrope withdrawal on morbidity and mortality in patients with chronic heart failure: results of the vesnarinone trial withdrawal substudy. Vest Withdrawal Substudy Group.
Soran O; Young JD; Holubkov R; Loftus S; Bourge R; Carson P; Jaski B; White BG; Feldman AM
J Card Fail; 1999 Sep; 5(3):195-200; discussion 201-2. PubMed ID: 10496192
[TBL] [Abstract][Full Text] [Related]
16. Vesnarinone-induced granulocytopenia: incidence in Japan and recommendations for safety.
Furusawa S; Ohashi Y; Asanoi H
J Clin Pharmacol; 1996 May; 36(5):477-81. PubMed ID: 8739027
[TBL] [Abstract][Full Text] [Related]
17. Acute hemodynamic effects of a new inotropic agent (OPC-8212) in patients with congestive heart failure.
Asanoi H; Sasayama S; Iuchi K; Kameyama T
J Am Coll Cardiol; 1987 Apr; 9(4):865-71. PubMed ID: 3558984
[TBL] [Abstract][Full Text] [Related]
18. Precautions for use and adverse effects of vesnarinone: potential mechanisms and future therapies.
Bertolet BD
Drug Saf; 2004; 27 Suppl 1():11-8. PubMed ID: 15293849
[TBL] [Abstract][Full Text] [Related]
19. The development of positive inotropic agents for chronic heart failure: how have we gone astray?
Packer M
J Am Coll Cardiol; 1993 Oct; 22(4 Suppl A):119A-126A. PubMed ID: 8397231
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a new inotropic agent, OPC-8212, in patients with dilated cardiomyopathy and heart failure.
Feldman AM; Becker LC; Llewellyn MP; Baughman KL
Am Heart J; 1988 Sep; 116(3):771-7. PubMed ID: 3046278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
